RCUS Arcus Corp Company Short-Term Debt

Arcus Biosciences - graphic logo of issuer RCUS

Arcus Biosciences, Inc. (RCUS) targets the colossal anti-tumor solutions market, actively expanding its network of strategic alliances with pharmaceutical behemoths. Business growth relies on the monetization of intellectual property and the global licensing of innovations. This chart illustrating the price evolution of the quotes shows the metric at 0.01. The company's operations are independent of economic cycles or seasonality, demonstrating resilience to macroeconomic shocks provided there is sufficient capital.

RCUS arcusbio.com Short-Term Debt (07/04/2022 - 10/31/2026)

Analytical breakdowns and data insights for company Arcus Corp (RCUS)

- current quotes and average value forecast:
Price Chart Arcus Biosciences|RCUS - Average Forecast Price
- market capitalization data:
Market Value Arcus Biosciences, Inc.|RCUS - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Arcus Biosciences|RCUS - Total Stockholders' Equity|Market Capitalization to Book Value Ratio arcusbio.com|RCUS - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Arcus Biosciences, Inc.|RCUS - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Arcus Biosciences, Inc.|RCUS - Aggregate Debt Obligations|Debts to Book Capitalization Arcus Biosciences, Inc.|RCUS - Long-Term Debt Volume|Company Short-Term Debt Arcus Biosciences|Quick Liquidity arcusbio.com
- earnings and multiples data:
RCUS - Net Income
General company analysis:Arcus Biosciences (RCUS)
Flagship merchandise of arcusbio.com

Investors are assessing the financial stability of Arcus Biosciences, Inc. (RCUS) through liquidity analysis. This indicator aggregates all credit obligations due for repayment within twelve months. The trend of short-term financial liabilities reflects current operating expenses. The stability of this metric confirms the efficiency of biocomponent logistics management and the absence of cash flow gaps. The final valuation requires comparing the volume of borrowings against the company's total revenue.

Competitors of Arcus Biosciences, Inc.

IBRX - Company Short-Term Debt|Short-Term Debt Immunocore Holdings|Janux Pharma (JANX) - Company Short-Term Debt|ZYME (Zymeworks Biopharmaceuticals) - Company Short-Term Debt|Company Short-Term Debt Tango Therapeutics|Short-Term Debt iovance.com IOVA|Company Short-Term Debts IMTX|Xencor Inc (XNCR) - Short-Term Indebtedness|Compass Bio - Company Current Liabilities|Replimune Inc. (REPL) - Short-Term Debt|LYEL: Company Current Liabilities|Company Short-Term Loans and Borrowings IPHA (innate-pharma.com)|PYXS: Company Short-Term Debts|CGEN - Short-Term Debt Volume|Company Short-Term Debt IO Biotech Corp|Company Current Liabilities Sutro Biopharma, Inc (STRO)|Company Short-Term Debt MiNK Therapeutics, Inc. (INKT)|Company Current Liabilities werewolftx.com HOWL|Immix Biopharma - Company Current Liabilities|Company Short-Term Debts alxoncology.com ALXO|CUE - Company Short-Term Debt|PDSB (PDS Biotechnology) - Company Short-Term Indebtedness|sonnetbio.com (SONN) - Company Short-Term Debt|Short-Term Debt MAIABiotech.com (MAIA)|Company Current Liabilities LIMN|LVTX - Short-Term Indebtedness|Company Current Liabilities NXTC (NextCure Corp)|Amount of Current Liabilities LPTX|Company Short-Term Debts INTS (Intensity Therapeutics, Inc.)|Company Short-Term Loans and Borrowings SNSE|Theriva Biologics - Company Short-Term Debts|Short-Term Debt Gritstone bio, Inc.|Kineta Bio (KA) - Company Short-Term Debt|NexImmune Corporation - Company Short-Term Loans and Borrowings|TSBX (Turnstone Biologics Corp) - Company Short-Term Debts|Company Short-Term Debts vaccinex.com|Company Short-Term Debt Harpoon Therapeutics, Inc. (HARP)